<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04987762</url>
  </required_header>
  <id_info>
    <org_study_id>ADA4004</org_study_id>
    <nct_id>NCT04987762</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children</brief_title>
  <official_title>An Open-Label, Multicenter, Multiple-Dose, Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children 4 to 12 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Purdue Pharma LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Purdue Pharma LP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the long-term safety of Adhansia XR in children and to&#xD;
      characterize the pharmacokinetics (PK) in 4 to 5 year-olds.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants with Adverse Events as a Measure of Safety</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Methylphenidate Concentrations from Multiple Doses of Adhansia XR in Children 4 to &lt;6 years of Age Who Have Been Diagnosed with Attention Deficit/Hyperactivity Disorder (ADHD)</measure>
    <time_frame>Post-dose PK sample collection within 26-hour timeframe</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Attention Deficit/Hyperactivity Disorder-Rating Scale, version 5 (ADHD-RS-5) Total Score</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Each of the 18 symptoms are rated on a 4-point scale from 0 (never or rarely) to 3 (very often), yielding a total score of 0 to 54.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Clinical Global Impression-Severity (CGI-S)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>At each visit, the clinician will use the CGI-S to rate the severity of a subject's condition on a scale that ranges from 1 (normal, not ill at all) to 7 (among the most extremely ill subjects).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Clinical Global Impression-Improvement (CGI-I)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>At each visit, the clinician will use the CGI-I to rate improvement relative to baseline on a scale from 1 (very much improved) to 7 (very much worse).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">159</enrollment>
  <condition>Attention Deficit/Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Adhansia XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adhansia XR capsules taken orally once daily in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adhansia XR</intervention_name>
    <description>Methylphenidate extended-release capsules taken once daily (12.5 mg, 25 mg, 35 mg, 45 mg, 55 mg, and 70 mg)</description>
    <arm_group_label>Adhansia XR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects ≥4 and ≤12 years of age at the time of informed&#xD;
             consent/assent.&#xD;
&#xD;
          -  Females of childbearing potential who are not pregnant and not nursing.&#xD;
&#xD;
          -  Females of childbearing potential who agree to practice a clinically accepted method&#xD;
             of contraception during the study and for at least 1 month prior to study dosing and 1&#xD;
             month following completion of the study. Acceptable contraceptive methods include&#xD;
             abstinence, oral contraception, surgical sterilization (bilateral tubal ligation,&#xD;
             bilateral oophorectomy, or hysterectomy), intrauterine device, or diaphragm in&#xD;
             addition to spermicidal foam and condom on male partner, or systemic contraception&#xD;
             (eg, levonorgestrel-releasing implant).&#xD;
&#xD;
          -  Diagnosis of ADHD (any type: combined, predominately hyperactive impulsive type or&#xD;
             predominately inattentive type) by a psychiatrist, psychologist, pediatrician, or&#xD;
             licensed allied healthcare professional using the Diagnostic and Statistical Manual of&#xD;
             Mental Disorders (DSM-5) and confirmed by administration of a structured diagnostic&#xD;
             interview using the Kiddie-Schedule for Affective Disorders and Schizophrenia for&#xD;
             School Age Children-Present and Lifetime DSM-5 version (K-SADS-PL).&#xD;
&#xD;
          -  Subjects who have received, or are receiving treatment with medication (amphetamine,&#xD;
             methylphenidate, or non-stimulant) for ADHD must be willing to undergo a washout&#xD;
             period of a minimum of 3 days or 5 half-lives (whichever is longer) prior to study&#xD;
             drug administration. The washout period for prohibited concomitant medications will be&#xD;
             at least 5 half-lives or 3 days, whichever is longer.&#xD;
&#xD;
          -  If subjects are currently off treatment, this must be for any reason other than&#xD;
             noncompliance, nonresponse, or intolerance to side effects.&#xD;
&#xD;
          -  Ratings on the attention deficit/hyperactivity disorder-Rating Scale, version 5 (ADHD&#xD;
             RS-5) when the subject is not receiving treatment for ADHD must be ≥90th percentile&#xD;
             normative value for sex and age in at least 1 of the categories: total score,&#xD;
             inattentive subscale, or hyperactive/impulse subscale.&#xD;
&#xD;
          -  Dissatisfied with his or her current pharmacological therapy for treatment of ADHD or&#xD;
             not currently receiving pharmacological therapy for ADHD for any reason other than&#xD;
             nonresponse, noncompliance, or tolerability issues with stimulants. Newly diagnosed&#xD;
             and treatment naïve subjects may be included at the discretion of the investigator.&#xD;
&#xD;
          -  Must be functioning at an age-appropriate level intellectually as determined by an&#xD;
             intelligence quotient (IQ) of ≥80 on a documented IQ assessment such as the Wechsler&#xD;
             Abbreviated Scale of Intelligence II (WASI-II) vocabulary and matrix reasoning&#xD;
             components, or the Kaufman Brief Intelligence Test, Second Edition (KBIT-2)&#xD;
&#xD;
          -  Parent(s)/legal guardian(s) must have the ability to read and understand the language&#xD;
             in which the informed consent is written and are mentally and physically competent to&#xD;
             provide written informed consent for their child.&#xD;
&#xD;
          -  Written or verbal assent from the subject (as applicable).&#xD;
&#xD;
          -  Subject and parent(s)/legal guardian/caregiver are willing and able to comply with all&#xD;
             the protocol requirements and parent(s)/legal guardian/caregiver must be able to&#xD;
             provide transportation for the subject to and from the clinic visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a known allergy, intolerance, or hypersensitivity to methylphenidate.&#xD;
&#xD;
          -  History of allergic reactions to tartrazine.&#xD;
&#xD;
          -  Known nonresponder to methylphenidate treatment.&#xD;
&#xD;
          -  Subject has received a monoamine oxidase inhibitor within 2 weeks before study&#xD;
             treatment.&#xD;
&#xD;
          -  Blood pressure and heart rate outside the 95th percentile for age and sex.&#xD;
&#xD;
          -  Subject has a current or recent history (within the past 6 months) of drug abuse or&#xD;
             dependence disorder; or someone in the subject's immediate family has a current or&#xD;
             recent history (within the past 6 months) of drug abuse or dependence disorder; or&#xD;
             someone living at the subject's home has a current or recent history (within the past&#xD;
             6 months) of drug abuse or dependence disorder; or subject has a positive urine drug&#xD;
             screen for stimulant medication (other than currently prescribed stimulant for the&#xD;
             treatment of ADHD) or drugs of abuse at the screening visit.&#xD;
&#xD;
          -  Has abnormal thyroid function, glaucoma, Gilles de la Tourette's disorder, a history&#xD;
             of seizures (except simple febrile seizures), or a tic disorder. Mild medication&#xD;
             induced tics are not exclusionary.&#xD;
&#xD;
          -  Primary and/or comorbid psychiatric diagnosis other than ADHD with the exception of&#xD;
             simple phobias, motor skill disorders, communication disorders, learning disorders,&#xD;
             and adjustment disorders so long as such disorder is judged not to interfere with&#xD;
             study participation or the safety of the subject.&#xD;
&#xD;
          -  Subjects with a family history (first-degree relatives) of sudden cardiac death&#xD;
             require review and approval by the medical monitor for participation in the study.&#xD;
&#xD;
          -  Subject has a history of disorders of the sensory organs, including deafness,&#xD;
             blindness or the subject is severely or profoundly developmentally disabled.&#xD;
&#xD;
          -  Any clinically significant abnormality or clinically significant abnormal laboratory&#xD;
             test results found during screening or a positive test for hepatitis A, hepatitis B,&#xD;
             hepatitis C, or HIV found during screening (subjects who have received a hepatitis A&#xD;
             vaccine and test positive for hepatitis A may be included in the study, at the&#xD;
             discretion of the investigator).&#xD;
&#xD;
          -  Use of an investigational drug within 30 days (90 days for biologics) or participation&#xD;
             in an investigational study within 30 days prior to dosing.&#xD;
&#xD;
          -  Any reason which, in the opinion of the investigator, would prevent the subject from&#xD;
             participating in the study.&#xD;
&#xD;
          -  Clinically significant ECG abnormalities (including but not limited to Wolff&#xD;
             Parkinson-White syndrome, supraventricular tachycardia, left ventricular hypertrophy,&#xD;
             abnormal conduction defect, or other cardiac arrhythmia), or vital sign abnormalities&#xD;
             (normal vital signs should be between 5th and 95th percentile for age) at screening.&#xD;
&#xD;
          -  Known history of cardiovascular disorders including hypertension, angina, arterial&#xD;
             occlusive disease, heart failure, hemodynamically significant congenital heart&#xD;
             disease, cardiomyopathies, myocardial infarction, potentially life-threatening&#xD;
             arrhythmias, and channelopathies (disorders caused by the dysfunction of ion&#xD;
             channels).&#xD;
&#xD;
          -  Clinically significant history of neurological, endocrinal (including thyrotoxicosis),&#xD;
             pulmonary, hematological, immunologic, gastrointestinal, renal, hepatic or metabolic&#xD;
             disease, or psychiatric illness other than ADHD.&#xD;
&#xD;
          -  History of anxiety, tension, agitation, motor tics, Tourette's syndrome or a family&#xD;
             history (first-degree relatives) of Tourette's syndrome.&#xD;
&#xD;
          -  History of glaucoma.&#xD;
&#xD;
          -  Has a positive serum pregnancy test (if applicable) at screening.&#xD;
&#xD;
          -  Positive findings on the Columbia-Suicide Severity Rating Scale (C-SSRS) for suicidal&#xD;
             ideation or behaviors at screening.&#xD;
&#xD;
          -  Clinically significant illness or surgery within 4 weeks prior to dosing. Subjects who&#xD;
             experience vomiting within 24 hours prior to clinic admission will be carefully&#xD;
             evaluated for upcoming illness/disease.&#xD;
&#xD;
          -  Hemoglobin &lt;105 g/L or hematocrit &lt;0.310 L/L at screening (subjects with abnormal&#xD;
             hemoglobin and/or hematocrit levels deemed not clinically significant may be included&#xD;
             in the study, at the discretion of the investigator).&#xD;
&#xD;
          -  Subject has received anticonvulsants (eg, phenobarbital, phenytoin, primidone),&#xD;
             coumarin anticoagulants, prescription pressor agents, pressor agents, guanethidine,&#xD;
             tricyclic antidepressants (imipramine, desipramine, selective serotonin inhibitors) or&#xD;
             herbal remedies within 30 days prior to the first dosing, or melatonin within 3 days&#xD;
             prior to the first dosing.&#xD;
&#xD;
        Other protocol specific inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Monica Morbidini</last_name>
    <phone>(919) 973-2981</phone>
    <email>MorbidiniMonica@prahs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Preferred Research Partners, Inc.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Adaptive Clinical Research, Inc.</name>
      <address>
        <city>Lauderhill</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Accel Research Sites - Maitland Clinical Research Unit</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta, LLC</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sisu BHR, LLC</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Southern Nevada, LLC</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IPS Research Company</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Red Oak Psychiatry Associates, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Family Psychiatry of the Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77381</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>methylphenidate</keyword>
  <keyword>Adhansia XR</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

